Evolus, Inc. (NASDAQ:EOLS) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. trimmed its stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 12.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 848,176 shares of the company's stock after selling 122,094 shares during the quarter. D. E. Shaw & Co. Inc. owned about 1.34% of Evolus worth $9,364,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in EOLS. Tri Locum Partners LP purchased a new stake in shares of Evolus during the fourth quarter worth approximately $8,198,000. Gilder Gagnon Howe & Co. LLC increased its stake in Evolus by 287.2% in the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company's stock valued at $7,753,000 after buying an additional 520,859 shares during the period. Caligan Partners LP increased its stake in Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock valued at $29,724,000 after buying an additional 498,900 shares during the period. Allostery Investments LP purchased a new position in Evolus during the 4th quarter worth $4,760,000. Finally, Altium Capital Management LLC lifted its stake in shares of Evolus by 93.0% in the 4th quarter. Altium Capital Management LLC now owns 685,000 shares of the company's stock worth $7,562,000 after acquiring an additional 330,000 shares during the period. 90.69% of the stock is owned by institutional investors and hedge funds.

Evolus Price Performance

EOLS traded up $0.03 on Tuesday, hitting $9.93. 145,274 shares of the company were exchanged, compared to its average volume of 901,419. Evolus, Inc. has a fifty-two week low of $8.67 and a fifty-two week high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The firm has a market capitalization of $639.92 million, a P/E ratio of -10.91 and a beta of 1.11. The business's fifty day moving average is $11.25 and its 200 day moving average is $12.26.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on EOLS shares. BTIG Research started coverage on shares of Evolus in a research note on Thursday, April 17th. They set a "buy" rating and a $21.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Evolus in a report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and set a $27.00 target price on shares of Evolus in a research note on Thursday, April 10th. Finally, Barclays raised their price target on Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $23.75.

Insider Transactions at Evolus

In related news, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the transaction, the insider now directly owns 508,619 shares of the company's stock, valued at approximately $6,306,875.60. The trade was a 1.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Karah Herdman Parschauer sold 12,888 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the completion of the sale, the director now directly owns 32,183 shares in the company, valued at $418,057.17. This trade represents a 28.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 86,241 shares of company stock valued at $1,048,666 in the last quarter. 5.90% of the stock is currently owned by corporate insiders.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.